SARS-CoV-2IgG

Niannian Lv1,2,3, Peng Chen4, Xiaobin Dai5

  • 1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

概括

低亲和度抗体可以通过诱导病毒聚合来中和SARS-CoV-2变种,如Omicron JN.1. 这项研究揭示了一种超出高亲和度结合的强效抗体中和的新机制.